Conditions: Healthy
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 16
Healthy volunteers: yes

Brief summary:
The main purpose of this study was to evaluate the safety and tolerability of nasal glucagon (NG). The study drug was delivered into the participant's nostril (intranasally) or was given as an injection just under the skin (subcutaneously) once in each of four study periods. The study lasted about 23 days for each participant.

Detailed description:

Arms:
arm 1: Ng dose at 0.5 milligram (mg) administered once in one of four study periods. arm 2: Ng dose at 1.0 milligram (mg) administered once in one of four study periods. arm 3: Ng dose at 2.0 milligram (mg) administered once in one of four study periods. arm 4: Subcutaneous (SC) glucagon dose of 1 mg, in one of four study periods.

Interventions: intervention 1: Nasal Glucagon intervention 2: Glucagon
Intervention descriptions: intervention 1: Administered intranasally. intervention 2: Administered SC.

Protocol document: